Results 241 to 250 of about 36,802 (283)
Some of the next articles are maybe not open access.
Current Hematologic Malignancy Reports, 2013
A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases.
Finazzi, G +2 more
openaire +2 more sources
A high risk of arterial and venous thrombosis is the hallmark of chronic myeloproliferative neoplasms (MPNs), particularly polycythemia vera (PV) and essential thrombocythemia (ET). Clinical aspects, pathogenesis and management of thrombosis in MPN resemble those of other paradigmatic vascular diseases.
Finazzi, G +2 more
openaire +2 more sources
An Immune Dysregulation in MPN
Current Hematologic Malignancy Reports, 2014Myeloproliferative neoplasms (MPNs) are stem cell-derived clonal myeloid malignancies characterized by a unique somatic mutational profile since three mutually exclusive mutations (JAK2V617F, MPL, and CALR) sustain the great majority of the cases. However, clinical observation that autoimmune diseases may predispose to MPNs, autoimmune disorders or ...
openaire +2 more sources
The roles of sex and genetics in the MPN
2022The Philadelphia chromosome negative myeloproliferative neoplasms(MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are acquired hematopoietic stem cell disorders driven by activating mutations of intracellular signal transduction pathways that control the production of circulating blood cells.
Alison R, Moliterno, Evan M, Braunstein
openaire +2 more sources
Myeloproliferative Neoplasien (MPN)
Der Klinikarzt, 2020ZUSAMMENFASSUNGAls „Myeloproliferative Neoplasien“ (MPN) werden eine Gruppe verschiedener maligner chronischer Erkrankungen der blutbildenden (Stamm-)Zellen des Knochenmarkes bezeichnet. Kennzeichnend für dieses Krankheitsbild ist eine gesteigerte Produktion von Erythrozyten, Leukozyten und/oder Thrombozyten.
Kim Kricheldorf +2 more
openaire +1 more source
Direct MPN for Faecal Coliform
Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Zweite Naturwissenschaftliche Abteilung: Mikrobiologie der Landwirtschaft, der Technologie und des Umweltschutzes, 1980Samples of Nile and Ismailia canal water were subjected to direct inoculation and incubation at elevated temperatures. The results obtained showed that the use of MacConkey broth medium was better than EC broth. In addition, the Direct MPN technique revealed to be suitable and superior by 90% of the examined samples.
M M, el-Abagy +2 more
openaire +2 more sources
Targets in MPNs and potential therapeutics
2022Philadelphia-negative classical Myeloproliferative Neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are clonal hemopathies that emerge in the hematopoietic stem cell (HSC) compartment.
Gabriel, Levy +6 more
openaire +2 more sources
Clinical Predictors of Outcome in MPN
Hematology/Oncology Clinics of North America, 2012Myeloproliferative neoplasms include 3 diseases: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET are dominated by a high risk of thrombosis and a late risk of clonal evolution into secondary MF and acute myeloid leukemia.
PASSAMONTI, FRANCESCO +4 more
openaire +4 more sources
Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets, 2011The four major entities that form the group of myeloproliferative neoplasms (MPN) are BCR-ABL positive chronic myeloid leukaemia (CML), chronic idiopathic myelofibrosis (CIMF), essential thrombocythemia (ET) and polycythemia vera (PV). All four are clonal diseases of the haematopoietic stem or precursor cell, they are of a chronic nature and ...
Susanne, Hofmann +2 more
openaire +2 more sources
Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO
Current Hematologic Malignancy Reports, 2019MDS/MPNs comprise a group of rare hematologic malignancies that balance features of myeloproliferation and bone marrow failure. Given overlapping clinical features and rarity of incidence, MDS/MPNs have long posed a diagnostic and therapeutic challenge.
Andrew T, Kuykendall, Eric, Padron
openaire +2 more sources
Overcoming “aspirin resistance” in MPN
Blood, 2012In this issue of Blood, Pascale and colleagues show that biochemical resistance to aspirin in patients with essential thrombocythemia (ET) can be reversed by twice-daily dosing ...
openaire +2 more sources